相关临床试验
6
1 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
N/A
进行中（未招募）
1
16.7%
已完成
3
50.0%
招募中
1
16.7%
撤回
1
16.7%
暂无批准数据
- China's National Medical Products Administration has granted Class III medical device approval to IceCure Medical's ProSense cryoablation system and associated cryoprobes. - ProSense uses liquid nitrogen-based cryoablation to destroy benign and malignant tumors in breast, kidney, bone and lung under imaging guidance. - The approval was supported by clinical data demonstrating safety and efficacy, particularly in breast tumors, and expands ProSense's reach beyond the U.S., Europe and Asia. - CEO Eyal Shamir called the decision a major milestone, with IceCure planning to accelerate commercialization in China through local partnerships.
- A Japanese study of 64 patients with stage I non-small cell lung cancer showed that combining stereotactic body radiation therapy with IceCure's cryoablation system achieved a 74% five-year overall survival rate, significantly higher than the 41-52% reported with radiation alone. - The combination therapy produced survival outcomes comparable to surgery, which has a five-year overall survival rate of 67-82% according to published studies, while maintaining a 93% local control rate. - The treatment demonstrated a 92% disease-specific five-year survival rate with no treatment-related mortality, offering a potentially less invasive alternative for patients with larger tumors measuring 2 cm or greater. - Lung cancer remains the most frequently diagnosed cancer worldwide with 2.5 million new cases annually, making these improved treatment outcomes particularly significant for patient care.
- IceCure Medical received a Notice of Allowance from the U.S. Patent and Trademark Office for its next-generation XSense cryoprobe technology designed to reduce tissue trauma during tumor extraction. - The company's XSense System has obtained regulatory approval in Israel for broad indications including breast cancer, gynecology, and oncology, following earlier FDA clearance in the United States. - The liquid-nitrogen-based cryoablation platform offers a minimally invasive alternative to surgical tumor removal, potentially reducing treatment costs and accelerating patient recovery times.
- Two peer-reviewed publications from the independent THERMAC trial demonstrate that IceCure's ProSense cryoablation system achieved the highest complete ablation rate compared to alternative thermal ablation techniques with no adverse events. - The study found that 95% of patients were very satisfied or satisfied with thermal ablation treatment, with superior cosmetic outcomes compared to breast-conserving surgery. - Based on the phase II results, investigators concluded that cryoablation is the preferred technique for comparison with surgery in a future phase III trial. - ProSense cryoablation was associated with zero cases requiring oncoplastic surgery, compared to 40% in the radiofrequency ablation group and 11% in the microwave ablation group.
- Multiple studies presented at major European oncology conferences demonstrate ProSense® cryoablation system's effectiveness with 94% complete ablation rate in early-stage breast cancer patients. - Patient satisfaction data reveals 95% of participants would choose cryoablation over traditional breast-conserving surgery, with 100% treatment tolerance and zero complications in key trials. - IceCure Medical's minimally invasive liquid nitrogen-based technology is gaining commercial traction in Europe, supported by growing evidence that cryoablation with adjuvant therapy produces recurrence rates comparable to surgical approaches.
- IceCure Medical has submitted a regulatory application to China's NMPA for its ProSense cryoablation system, building upon their existing IceSense3 platform already approved in the market. - The ProSense system utilizes liquid nitrogen technology to create lethal zones for tumor destruction, featuring five specialized cryoprobes for various surgical applications including breast and lung procedures. - The portable system offers minimally invasive tumor treatment with shorter recovery times, positioning IceCure to expand its presence in China's growing medical device market.
- IceCure Medical reported a 42% increase in North American sales of its ProSense cryoablation system in 2024, signaling growing adoption for breast tumor treatment. - The company anticipates an FDA decision on ProSense for early-stage breast cancer in Q1 2025, following positive advisory panel feedback based on the ICE3 study. - ICE3 study results showed a 96.3% recurrence-free rate and 100% patient/physician satisfaction, aligning with lumpectomy outcomes for early-stage breast cancer. - Interim results from the ICESECRET kidney cancer study demonstrated an 88.7% recurrence-free rate, highlighting ProSense's potential in treating kidney cancer.
- IceCure Medical's ProSense system received a favorable recommendation from the FDA Medical Device Advisory Committee for treating early-stage, low-risk breast cancer. - The FDA's positive assessment enhances the likelihood of final FDA approval, expected by the end of Q1 2025, potentially catalyzing the system's adoption. - IceCure Medical's financial position is stable, with $10.7 million in cash and no debt as of September 30, 2024, alongside a 98% year-over-year revenue increase in Q3 2024.
- An FDA advisory panel has favorably recommended IceCure Medical's ProSense cryoablation system for treating early-stage, low-risk breast cancer. - The panel voted 9-5 that the benefits of ProSense outweigh the risks when used with adjuvant endocrine therapy, offering a potential alternative to lumpectomy. - The FDA's final decision on marketing authorization for ProSense is expected in the first quarter of 2025. - ProSense uses liquid nitrogen to freeze and destroy tumors, providing a minimally invasive treatment option.
- The FDA's Medical Device Advisory Committee will review IceCure's ProSense cryoablation system for early-stage, low-risk breast cancer on November 7, 2024. - The advisory panel will provide recommendations on the benefit-risk profile of ProSense for treating early-stage invasive breast cancer with cryoablation and adjuvant endocrine therapy. - Public comments from stakeholders, including patients and healthcare professionals, are available on the FDA website for the advisory panel's consideration. - The FDA's decision on marketing authorization for ProSense is expected by early 2025, following the advisory panel's vote.
